Testing Menu
Absolute Genomics is a high-complexity CLIA and CAP accredited laboratory that provides a wide variety of molecular diagnostic testing. The laboratory staff at Absolute Genomics is highly trained and experienced, which is reflected by our seamless testing and customer service efforts. Molecular diagnosis of infectious disease is the focus and specialty of Absolute Genomics. To achieve this goal, we have ten panels: COVID-19 testing, Respiratory InSITE, Urinary InSITE, STI InSITE, Women’s Health InSITE, Sexual Health InSITE, Wound InSITE, Nail InSITE, PGx testing and Antibiotic Resistance (ABx Advantage). These panels are designed based on epidemiological data from the CDC, NIH, and other established national organizations.
Individual pathogen targets selected for each panel went through several phases of data analysis and curation to establish contribution in disease causation. Relevant research articles and epidemiological databases are used as sources for selecting the pathogens that were most strongly related to a specific disease. Absolute Genomics prides itself on collecting and utilizing feedback from clients regarding the clinical relevance and diversity of pathogens on the panels. For example, the Absolute Genomics Respiratory InSITE panel is comprised of several viruses, bacterial ,and fungal targets. Within the genera, some of the pathogens are tested at the species level that gives more depth to the test. The ABx Advantage panel allows physicians to make better choices to treat drug resistance pathogens. The advantage with ABx Advantage panel is that it provides a single multi-potent drug choice as a treatment option. This superior technology relies on artificial intelligence, machine learning, and human expertise to provide doctors the best available treatment in a molecular test. When dealing with poly infection, doctors opt for multiple drugs. However, with Absolute Genomics stewardship they can confidently use a single antibiotic that would be effective against several pathogens. This is achieved by looking into multiple factors like site of infection, pathogens, detected resistance gene markets, drug induced allergies, age, and gender.
“Individual pathogen targets selected for each panel went through several phases of data analysis and curation to establish contribution in disease causation. Relevant research articles and epidemiological databases are used as sources for selecting the pathogens that were most strongly related to a specific disease. Absolute Genomics prides itself on collecting and utilizing feedback from clients regarding the clinical relevance and diversity of pathogens on the panels. The Absolute Genomics Respiratory InSITE panel is comprised of several viruses, bacterial and fungal targets. Within the genera, some of the pathogens are tested at the species level that gives more depth to the test. This panel can be vital for high-risk populations such as immunocompromised patients, children, and older adults. Early diagnosis and treatment can reduce morbidity and mortality associated with such high-risk populations. The ABx Advantage panel allows physicians to make better choices to treat antibiotic resistant pathogens. The advantage with ABx Advantage panel is that it provides a single multi-potent drug choice as a treatment option. This superior technology relies on artificial intelligence, machine learning, and human expertise to provide doctors the best available treatment in a molecular test. When dealing with poly infection, doctors opt for multiple antibiotics. However, with Absolute Genomics stewardship they can confidently use a single antibiotic that would be effective against several pathogens. This is achieved by looking into multiple factors like site of infection, pathogens, detected resistance gene markets, drug induced allergies, age, and gender. Absolute Genomics is committed to innovation and excellence in molecular diagnostics”
Absolute Genomics is committed to innovation and excellence in molecular diagnostics. Currently, several research and development projects are being pursued ranging from metagenomics to germline next generation sequencing for genetic disorders.
Dr. John Hanson, MD, PhD, Laboratory Director
